Breast Cancer Stem Cells May Be Key to Multi-drug Resistance – 2
Narrator: This is NIH Health Matters. When cells in breast cancer tumors stop responding to drugs, it’s called multi-drug resistance. Dr. Michael Gottesman, director of clinical research at the National Cancer Institute explains that cancer stem cells may cause that resistance.
Dr. Gottesman: The basis for that resistance is a residual group of cells within the tumor that have been called cancer stem cells.
Narrator: Dr. Gottesman is leading a study that examines breast cancer stem cells.
Dr. Gottesman: Our original idea was to look at those cells and ask whether they expressed some of the markers associated with drug resistance, and indeed they do.
Narrator: For more information on breast cancer stem cells and multi-drug resistance, visit www.cancer.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Audio
NIH Audio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Audio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Audio is a service of the Office of Communications & Public Liaison.